Global Allergy Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

List of Tables

The global demand for Allergy Immunotherapy Market is presumed to reach the valuation of nearly USD 7.08 MN by 2030 from USD 3.27 MN in 2022 with a CAGR of 13.97% under the study period of 2023-2030.

Allergy immunotherapy is a medical treatment used to reduce or stop allergy attacks caused by exposure to allergens like grass pollens, house dust mites, and bee venom. The typical treatment method involves regular allergy shots containing a tiny amount of the allergens triggering the allergic reactions to stimulate the immune system. Different types of immunotherapy exist based on the administration route. The effectiveness of this therapy depends on the length of the treatment program and the dose of the allergen.

Market Dynamics:

Both children and adults can undergo allergy immunotherapy. While treating older adults using allergy immunotherapy, their pre-existing medical conditions are taken into consideration. The cost of the allergen immunotherapy varies by country and administration route. Rising pollution levels and the prevalence of chronic disorders due to allergic reactions will serve as the main impetus for this market's growth. The effectiveness of immunotherapy in treating different types of allergies like allergic rhinitis, allergic asthma, conjunctivitis (eye allergy), or stinging insect allergy compared to traditional methods will benefit this market's growth. Growing awareness and approval for an immunotherapy-based treatment for allergies in patients of all age groups will boost the market growth. Increased healthcare investments in the research and development of high-quality allergy shots to cover several types of known allergens will be a market booster. The major hurdle for the growth of this market is the lack of awareness about allergy immunotherapy.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each segment in the global market of allergy immunotherapy.

Market Segmentation:

This section of the allergy immunotherapy market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.

By Treatment Type

Subcutaneous Immunotherapy (SCIT)
Sublingual Immunotherapy (SLIT)

By Allergy Type

Allergic Rhinitis
Allergic Asthma
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Regional Analysis:

This section covers regional segmentation which accentuates on current and future demand for Allergy Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the allergy immunotherapy market include Adamis Pharmaceuticals Corporation,ALK-Abello A/S,Allergy Therapeutics,ASIT Biotech,Circassia,DVB Technologies SA,DESENTUM OY,HAL Allergy B.V.,HollisterStier Allergy,LETIPharma,Merck KGaA,Mylan N.V.,Stallergenes Greer plc. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11213853

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ALLERGY IMMUNOTHERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 By Treatment Type
- 3.7.2 By Allergy Type
- 3.7.3 By Distribution Channel
- 3.7.4 By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ALLERGY IMMUNOTHERAPY MARKET ANALYSIS BY TREATMENT TYPE

6.1 Overview by Treatment Type
6.2 Historical and Forecast Data
6.3 Analysis by Treatment Type
6.4 Subcutaneous Immunotherapy (SCIT) Market by Regions
6.6 Sublingual Immunotherapy (SLIT) Market by Regions

7 . GLOBAL ALLERGY IMMUNOTHERAPY MARKET ANALYSIS BY ALLERGY TYPE

7.1 Overview by Allergy Type
7.2 Historical and Forecast Data
7.3 Analysis by Allergy Type
7.4 Allergic rhinitis Market by Regions
7.5 Allergic asthma Market by Regions
7.6 Others Market by Regions

8 . GLOBAL ALLERGY IMMUNOTHERAPY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1 Overview by Distribution Channel
8.2 Historical and Forecast Data
8.3 Analysis by Distribution Channel
8.4 Hospital Pharmacy Market by Regions
8.5 Retail Pharmacy Market by Regions
8.6 Online Pharmacy Market by Regions

9 . GLOBAL ALLERGY IMMUNOTHERAPY MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America
- 9.3.1. Overview, Historic and Forecast Data
- 9.3.2. North America By Segment
- 9.3.3. North America By Country
- 9.3.4. United State
- 9.3.5. Canada
- 9.3.6. Mexico
9.4. Europe
- 9.4.1. Overview, Historic and Forecast Data
- 9.4.2. Europe by Segment
- 9.4.3. Europe by Country
- 9.4.4. United Kingdom
- 9.4.5. France
- 9.4.6. Germany
- 9.4.7. Italy
- 9.4.8. Russia
- 9.4.9. Rest Of Europe
9.5. Asia Pacific
- 9.5.1. Overview, Historic and Forecast Data
- 9.5.2. Asia Pacific by Segment
- 9.5.3. Asia Pacific by Country
- 9.5.4. China
- 9.5.5. India
- 9.5.6. Japan
- 9.5.7. South Korea
- 9.5.8. Australia
- 9.5.9. Rest Of Asia Pacific
9.6. Latin America
- 9.6.1. Overview, Historic and Forecast Data
- 9.6.2. Latin America by Segment
- 9.6.3. Latin America by Country
- 9.6.4. Brazil
- 9.6.5. Argentina
- 9.6.6. Peru
- 9.6.7. Chile
- 9.6.8. Rest of Latin America
9.7. Middle East & Africa
- 9.7.1. Overview, Historic and Forecast Data
- 9.7.2. Middle East & Africa by Segment
- 9.7.3. Middle East & Africa by Country
- 9.7.4. Saudi Arabia
- 9.7.5. UAE
- 9.7.6. Israel
- 9.7.7. South Africa
- 9.7.8. Rest Of Middle East And Africa

10 . COMPETITIVE LANDSCAPE OF THE ALLERGY IMMUNOTHERAPY COMPANIES

10.1. Allergy Immunotherapy Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF ALLERGY IMMUNOTHERAPY INDUSTRY

11.1. Company Share Analysis
11.2. Market Concentration Rate
11.3. Adamis Pharmaceuticals Corporation
- 11.3.1. Company Overview
- 11.3.2. Financials
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. ALK-Abello A/S
- 11.4.1. Company Overview
- 11.4.2. Financials
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Allergy Therapeutics
- 11.5.1. Company Overview
- 11.5.2. Financials
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. ASIT Biotech
- 11.6.1. Company Overview
- 11.6.2. Financials
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Circassia
- 11.7.1. Company Overview
- 11.7.2. Financials
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. DVB Technologies SA
- 11.8.1. Company Overview
- 11.8.2. Financials
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. DESENTUM OY
- 11.9.1. Company Overview
- 11.9.2. Financials
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. HAL Allergy B.V.
- 11.10.1. Company Overview
- 11.10.2. Financials
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. HollisterStier Allergy
- 11.11.1. Company Overview
- 11.11.2. Financials
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. LETIPharma
- 11.12.1. Company Overview
- 11.12.2. Financials
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Merck KGaA
- 11.13.1. Company Overview
- 11.13.2. Financials
- 11.13.3. Products
- 11.13.4. Recent Developments
11.14. Mylan N.V.
- 11.14.1. Company Overview
- 11.14.2. Financials
- 11.14.3. Products
- 11.14.4. Recent Developments
11.15. Stallergenes Greer plc
- 11.15.1. Company Overview
- 11.15.2. Financials
- 11.15.3. Products
- 11.15.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies